Protagenic Therapeutics, Inc. Warrant (PTIXW)

• Market cap: $1.09M
• 1 day: 100.00%
• 5 days: 913.51%
• 1 month: 3,650.00%
• 3 months: 3,233.33%
• 6 months: 1,775.00%
• Year to date: 2,207.69%
• 1 year: 546.55%
• 5 years: -54.55%
• 10 years: -54.55%
• Sector: Healthcare
• Industry: Biotechnology

About: Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Employees: 3

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

78% more capital invested

Capital invested by funds: $1.48K [Q4 2024] → $2.63K (+$1.15K) [Q1 2025]

1.37% more ownership

Funds ownership: 6.3% [Q4 2024] → 7.67% (+1.37%) [Q1 2025]

0% more funds holding

Funds holding: 6 [Q4 2024] → 6 (+0) [Q1 2025]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3